Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Placebo + Nab-paclitaxel + Doxorubicin + Cyclophosphamide + Filgrastim + Pegfilgrastim
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Triple-negative Breast Cancer
Conditions
Triple-negative Breast Cancer
Trial Timeline
Jul 24, 2017 → Sep 28, 2022
NCT ID
NCT03197935About Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Placebo + Nab-paclitaxel + Doxorubicin + Cyclophosphamide + Filgrastim + Pegfilgrastim
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Placebo + Nab-paclitaxel + Doxorubicin + Cyclophosphamide + Filgrastim + Pegfilgrastim is a phase 3 stage product being developed by Roche for Triple-negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03197935. Target conditions include Triple-negative Breast Cancer.
What happened to similar drugs?
1 of 6 similar drugs in Triple-negative Breast Cancer were approved
Approved (1) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03197935 | Phase 3 | Completed |
Competing Products
20 competing products in Triple-negative Breast Cancer